

Group I: Claims 1-4, drawn to isolated nucleic acids encoding MDK1 polypeptides, recombinant nucleic acids encoding MDK1 polypeptides and vectors, and nucleic acid probes, classified in Class 536, subclasses 23.1 and 24.31.

Group II: claim 5, drawn to the MDK1 polypeptide, classified in Class 530, subclass 350.

Group III: claims 6 and 7, drawn to antibodies specific for MDK1 and hybridomas secreting anti-MDK1 antibodies, classified in Class 530, subclass 387.9 and Class 435, subclass 240.27.

Group IV: claims 8 and 10-14, drawn to assays for detection of MDK1 binding partners and detection of compounds capable of affecting the binding interactions of MDK1, classified in Class 436, subclass 501.

Group V: claim 9, drawn to a therapeutic method, classified in Class 424, subclass 184.1.

Group VI: claim 15, drawn to a diagnostic method, classified in Class 435, subclass 7.23.

ELECTION


Applicant hereby elects to prosecute the claims of group I with traverse. Applicant has also added new claims that it believes belong with this group and which are fully supported by the original specification, thereby adding no new matter.

If any fees are due in connection with this response, please charge Deposit Account 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON

By



Charles S. Berkman
Reg. No. 38,077

sls
First Interstate World Center
633 West Fifth Street, 47th Floor
Los Angeles, CA 90071-2066
(619) 552-8400